Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.

Increasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the...

Full description

Bibliographic Details
Main Authors: Milan Scheidegger, Martin Walter, Mick Lehmann, Coraline Metzger, Simone Grimm, Heinz Boeker, Peter Boesiger, Anke Henning, Erich Seifritz
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3461985?pdf=render
_version_ 1818956271201550336
author Milan Scheidegger
Martin Walter
Mick Lehmann
Coraline Metzger
Simone Grimm
Heinz Boeker
Peter Boesiger
Anke Henning
Erich Seifritz
author_facet Milan Scheidegger
Martin Walter
Mick Lehmann
Coraline Metzger
Simone Grimm
Heinz Boeker
Peter Boesiger
Anke Henning
Erich Seifritz
author_sort Milan Scheidegger
collection DOAJ
description Increasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the most abundant and major excitatory neurotransmitter in the brain, pathophysiological changes in glutamatergic signaling are likely to affect neurobehavioral plasticity, information processing and large-scale changes in functional brain connectivity underlying certain symptoms of major depressive disorder. Using resting state functional magnetic resonance imaging (rsfMRI), the "dorsal nexus "(DN) was recently identified as a bilateral dorsal medial prefrontal cortex region showing dramatically increased depression-associated functional connectivity with large portions of a cognitive control network (CCN), the default mode network (DMN), and a rostral affective network (AN). Hence, Sheline and colleagues (2010) proposed that reducing increased connectivity of the DN might play a critical role in reducing depression symptomatology and thus represent a potential therapy target for affective disorders. Here, using a randomized, placebo-controlled, double-blind, crossover rsfMRI challenge in healthy subjects we demonstrate that ketamine decreases functional connectivity of the DMN to the DN and to the pregenual anterior cingulate (PACC) and medioprefrontal cortex (MPFC) via its representative hub, the posterior cingulate cortex (PCC). These findings in healthy subjects may serve as a model to elucidate potential biomechanisms that are addressed by successful treatment of major depression. This notion is further supported by the temporal overlap of our observation of subacute functional network modulation after 24 hours with the peak of efficacy following an intravenous ketamine administration in treatment-resistant depression.
first_indexed 2024-12-20T10:51:18Z
format Article
id doaj.art-096314e374d342f1b21dedae414b5ab3
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-20T10:51:18Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-096314e374d342f1b21dedae414b5ab32022-12-21T19:43:14ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0179e4479910.1371/journal.pone.0044799Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.Milan ScheideggerMartin WalterMick LehmannCoraline MetzgerSimone GrimmHeinz BoekerPeter BoesigerAnke HenningErich SeifritzIncreasing preclinical and clinical evidence underscores the strong and rapid antidepressant properties of the glutamate-modulating NMDA receptor antagonist ketamine. Targeting the glutamatergic system might thus provide a novel molecular strategy for antidepressant treatment. Since glutamate is the most abundant and major excitatory neurotransmitter in the brain, pathophysiological changes in glutamatergic signaling are likely to affect neurobehavioral plasticity, information processing and large-scale changes in functional brain connectivity underlying certain symptoms of major depressive disorder. Using resting state functional magnetic resonance imaging (rsfMRI), the "dorsal nexus "(DN) was recently identified as a bilateral dorsal medial prefrontal cortex region showing dramatically increased depression-associated functional connectivity with large portions of a cognitive control network (CCN), the default mode network (DMN), and a rostral affective network (AN). Hence, Sheline and colleagues (2010) proposed that reducing increased connectivity of the DN might play a critical role in reducing depression symptomatology and thus represent a potential therapy target for affective disorders. Here, using a randomized, placebo-controlled, double-blind, crossover rsfMRI challenge in healthy subjects we demonstrate that ketamine decreases functional connectivity of the DMN to the DN and to the pregenual anterior cingulate (PACC) and medioprefrontal cortex (MPFC) via its representative hub, the posterior cingulate cortex (PCC). These findings in healthy subjects may serve as a model to elucidate potential biomechanisms that are addressed by successful treatment of major depression. This notion is further supported by the temporal overlap of our observation of subacute functional network modulation after 24 hours with the peak of efficacy following an intravenous ketamine administration in treatment-resistant depression.http://europepmc.org/articles/PMC3461985?pdf=render
spellingShingle Milan Scheidegger
Martin Walter
Mick Lehmann
Coraline Metzger
Simone Grimm
Heinz Boeker
Peter Boesiger
Anke Henning
Erich Seifritz
Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
PLoS ONE
title Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
title_full Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
title_fullStr Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
title_full_unstemmed Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
title_short Ketamine decreases resting state functional network connectivity in healthy subjects: implications for antidepressant drug action.
title_sort ketamine decreases resting state functional network connectivity in healthy subjects implications for antidepressant drug action
url http://europepmc.org/articles/PMC3461985?pdf=render
work_keys_str_mv AT milanscheidegger ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT martinwalter ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT micklehmann ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT coralinemetzger ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT simonegrimm ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT heinzboeker ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT peterboesiger ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT ankehenning ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction
AT erichseifritz ketaminedecreasesrestingstatefunctionalnetworkconnectivityinhealthysubjectsimplicationsforantidepressantdrugaction